Matthew H. Kulke, MD, Dana-Farber Cancer Institute

Matthew H. Kulke, MD, provides a broad overview of initial therapy options available for patients with neuroendocrine tumors.

Expert insight on the subtypes of neuroendocrine tumors and current understanding of the disease microenvironment.